Addendum

Letermovir (prophylaxis of CMV reactivation and disease after stem cell transplantation) - Addendum to Project A23-139

Report documents

Indication:

Prophylaxis of CMV reactivation and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant.

Result of dossier assessment:

Unchanged after addendum:
hint of non-quantifiable added benefit

2024-06-06 A G-BA decision was published.

Project no.: A24-48
Commission: Commission awarded on 23.04.2024 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Immune system and infections
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI: https://doi.org/10.60584/A24-48_en

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.